Stack Guides

Best Stack for Heart Health: Evidence-Based Combinations

Heart health isn't achieved through a single intervention—it's the result of optimizing multiple physiological pathways simultaneously. Whether you're...

Last Updated:

Best Stack for Heart Health: Evidence-Based Combinations

Heart health isn't achieved through a single intervention—it's the result of optimizing multiple physiological pathways simultaneously. Whether you're managing blood pressure, improving lipid profiles, reducing visceral fat, or preventing cardiovascular events, strategic supplementation and peptide therapy can amplify results beyond what diet and exercise alone can deliver.

This guide presents an evidence-based framework for building a heart health stack using compounds ranked by clinical efficacy, supported by meta-analyses and randomized controlled trials. The goal is simple: maximize cardiovascular benefits while maintaining cost-effectiveness and minimizing interactions.

The Strategic Stack Framework

Rather than recommending random compounds, we'll organize heart health interventions into three tiers:

  • Foundation Stack: Cost-effective, evidence-dense compounds targeting multiple pathways
  • Enhancement Stack: Add-ons that amplify specific benefits or address individual risk factors
  • Advanced Stack: Peptide therapies for patients with substantial risk or metabolic dysfunction

This allows you to start simple and progressively optimize based on your individual needs, biomarkers, and response.

Foundation Stack: The Essentials

The foundation stack contains compounds with the highest evidence-to-cost ratio. These are compounds that should form the baseline for virtually anyone serious about heart health.

Omega-3 Fatty Acids (1000-3000mg EPA+DHA daily)

The Evidence: Omega-3 fatty acids remain one of the most studied interventions for cardiovascular health. A meta-analysis of 16 randomized controlled trials found that fish oil supplementation reduced triglycerides by 25.50 mg/dL compared to placebo, while simultaneously increasing HDL cholesterol by 2.54 mg/dL. These improvements directly reduce cardiovascular event risk.

Mechanism: EPA and DHA work through multiple pathways—reducing inflammation, stabilizing plaque, improving endothelial function, and decreasing triglyceride production in the liver.

Dosing: Start with 1000-2000mg combined EPA+DHA daily (from fish oil or algae-based sources), divided into one or two doses with meals to minimize GI upset. High-dose applications (3000-4000mg) are useful for elevated triglycerides but should be monitored for blood thinning effects.

Timing: Take with meals to enhance absorption and reduce fishy aftertaste.

Cost: $10-$60/month depending on source quality and concentration.

Note: Choose forms with 60%+ EPA+DHA content to reduce pill burden.


Berberine (500mg three times daily)

The Evidence: Berberine stands out as one of the few supplements with plant-based origins and robust clinical evidence. A recent meta-analysis found that berberine reduced triglycerides by 0.367 mmol/L, total cholesterol by 0.451 mmol/L, and LDL cholesterol by 0.495 mmol/L—effect sizes approaching those of some pharmaceutical interventions.

Mechanism: Berberine activates AMP-activated protein kinase (AMPK), which regulates glucose metabolism, lipid synthesis, and inflammation. It also improves insulin sensitivity and reduces endothelial dysfunction.

Dosing: 500mg three times daily with meals. Consistent dosing across the day is more effective than single large doses.

Timing: Take with breakfast, lunch, and dinner to maintain steady-state levels and improve GI tolerance.

Cost: $15-$45/month.

Synergy Note: Berberine pairs exceptionally well with other lipid-lowering compounds and acts synergistically with lifestyle interventions to reduce blood glucose.


Magnesium (200-400mg elemental daily)

The Evidence: A meta-analysis of 38 RCTs found that magnesium supplementation reduced systolic blood pressure by 2.81 mmHg and diastolic pressure by 2.05 mmHg. In hypertensive patients already on medication, the effect jumped to 7.68 mmHg systolic reduction—a clinically meaningful improvement that can meaningfully reduce medication requirements.

Mechanism: Magnesium acts as a natural calcium antagonist, improving vascular smooth muscle relaxation and endothelial function. It also regulates blood viscosity and reduces inflammatory markers.

Dosing: 200-400mg of elemental magnesium daily. Verify the form: magnesium glycinate and magnesium malate are better absorbed than oxide (which acts as a laxative). Take a single dose in the evening if possible, as magnesium has mild relaxation properties.

Timing: Evening, taken 2-3 hours before bed to avoid GI disturbances and leverage mild sleep-promoting effects.

Cost: $12-$45/month.

Interaction Note: Magnesium can reduce absorption of some medications (fluoroquinolones, tetracyclines, and bisphosphonates). Separate by 2 hours.


CoQ10 (100-300mg once or twice daily)

The Evidence: CoQ10 is essential for mitochondrial ATP production and acts as a powerful antioxidant in cardiac tissue. A meta-analysis of 16 RCTs in Type 2 Diabetes patients found that CoQ10 reduced systolic blood pressure by 3.86 mmHg and diastolic pressure by 2.70 mmHg. Additional evidence shows improvements in endothelial function and energy production in cardiac myocytes.

Mechanism: CoQ10 directly supports mitochondrial respiration in heart cells, reduces oxidative stress, and improves arterial compliance. It's particularly beneficial in patients taking statins, which deplete endogenous CoQ10.

Dosing: 100-300mg daily, preferably taken with dietary fat to enhance absorption (ubiquinol form has superior bioavailability compared to ubiquinone). Some patients benefit from split dosing (150mg twice daily) to maintain higher steady-state levels.

Timing: With breakfast and lunch (with fat-containing meals).

Cost: $20-$75/month depending on form and brand.

Clinical Note: If you're taking statins, CoQ10 is nearly mandatory—statins reduce endogenous CoQ10 by up to 40%, which may explain some side effects.


Curcumin (500-1000mg twice daily)

The Evidence: Curcumin, the active component of turmeric, demonstrates strong evidence for cardiovascular health. A meta-analysis of 64 RCTs found that curcumin reduced LDL cholesterol by 4.89 mg/dL and increased HDL cholesterol by 1.80 mg/dL. Beyond lipid benefits, curcumin reduces arterial inflammation, improves endothelial function, and decreases C-reactive protein—a key marker of cardiovascular inflammation.

Mechanism: Curcumin modulates NF-κB signaling (the master inflammation pathway), reduces lipid oxidation, and improves flow-mediated dilation in arteries.

Dosing: 500-1000mg twice daily with meals. Bioavailability is notoriously poor; choose formulations with black pepper extract (piperine) or phospholipid-bound curcumin (e.g., Meriva or BCM-95), which increase absorption 20-40 fold.

Timing: Morning and evening with meals containing fat.

Cost: $10-$55/month.

Note: Standard turmeric powder is insufficient; you need standardized curcumin extracts (>90% curcuminoids).


Build Your Evidence-Based Stack

Use our stack builder to find the best compounds for your health goals, ranked by scientific evidence.

Enhancement Stack: Targeted Optimizations

Once the foundation is in place, these compounds address specific cardiovascular risk factors or amplify results in particular populations.

Black Seed Oil (1000-3000mg twice daily)

The Evidence: A massive meta-analysis of 82 RCTs (5,026 participants) found that black seed oil improved systolic BP, diastolic BP, mean arterial pressure, total cholesterol, LDL-C, HDL-C, fasting blood sugar, HbA1c, and multiple inflammatory markers (CRP, IL-6, TNF-α).

Best For: Patients with hypertension, elevated inflammatory markers, or metabolic syndrome.

Dosing: 1000-3000mg twice daily with meals.

Cost: $10-$35/month.


Aged Garlic Extract (600-1200mg once daily)

The Evidence: A meta-analysis of 9 RCTs (n=584) found that aged garlic extract reduced systolic BP by 4.03 mmHg in hypertensive patients. Additional benefits include reduced arterial calcification and improved lipid profiles.

Best For: Hypertensive patients or those with calcified coronary plaques.

Dosing: 600-1200mg once daily.

Timing: Morning with breakfast.

Cost: $12-$35/month.


Psyllium Husk (5-10g, 1-3 times daily)

The Evidence: A meta-analysis of 28 RCTs (n=1924) found that psyllium husk reduced LDL cholesterol by 0.33 mmol/L at a median dose of 10.2 g/day. It also improves glycemic control and supports healthy body weight.

Best For: Elevated LDL cholesterol, poor lipid ratios, or constipation.

Dosing: 5-10g per dose, 1-3 times daily, with 8+ oz water.

Timing: 30 minutes before meals or 2 hours after medications.

Cost: $8-$25/month.


Alpha-Lipoic Acid (300-600mg once or twice daily)

The Evidence: A meta-analysis of 63 RCTs found that ALA reduced insulin resistance (HOMA-IR by 0.74 units), fasting glucose by 5.28 mg/dL, HbA1c by 0.40%, and triglycerides by 2.90 mg/dL. These improvements cascade into reduced cardiovascular risk.

Best For: Insulin resistance, Type 2 Diabetes, or metabolic dysfunction.

Dosing: 300-600mg once or twice daily on an empty stomach (or with a light meal if GI upset occurs).

Timing: Morning and evening, away from food for optimal absorption.

Cost: $10-$45/month.


Pycnogenol (100-200mg once daily)

The Evidence: Meta-analyses of 7-27 RCTs found that Pycnogenol reduced systolic BP by 2.26-3.22 mmHg and diastolic BP by 1.76-2.62 mmHg, with additional benefits for endothelial function and glucose control.

Best For: Patients seeking antioxidant benefits and improved vascular function.

Dosing: 100-200mg once daily with meals.

Cost: $20-$55/month.


Melatonin (0.5-5mg once daily)

The Evidence: Multiple meta-analyses found that melatonin reduced systolic BP by 2.34-3.43 mmHg and diastolic BP by 3.33 mmHg. Beyond blood pressure, melatonin protects mitochondrial function and reduces nocturnal inflammation—key factors in cardiovascular disease.

Best For: Sleep quality and circadian rhythm optimization; hypertension management.

Dosing: 0.5-5mg in the evening, starting at the lower end to assess tolerance.

Timing: 30-60 minutes before bedtime.

Cost: $4-$20/month.


Spirulina (1-3g once daily)

The Evidence: Meta-analysis of RCTs found that spirulina reduced systolic BP by 4.41 mmHg and diastolic BP by 2.84 mmHg, with additional benefits for lipid profiles and glucose control, particularly in hypertensive and overweight populations.

Best For: Broad spectrum cardiovascular and metabolic support.

Dosing: 1-3g once daily (split into two doses if GI tolerance is an issue).

Timing: Morning with breakfast.

Cost: $8-$35/month.


Grape Seed Extract (150-300mg once daily)

The Evidence: A meta-analysis of 19 RCTs found that grape seed extract reduced diastolic BP by 2.20 mmHg, with greater systolic reductions (6.08 mmHg) in younger and obese subgroups. Evidence also supports improved endothelial function and reduced arterial stiffness.

Best For: Endothelial dysfunction and diastolic hypertension.

Dosing: 150-300mg once daily.

Cost: $8-$30/month.


Whey Protein (20-40g once or twice daily)

The Evidence: A meta-analysis of 18 RCTs found that whey protein reduced systolic BP by 1.54 mmHg, with greater effects at doses >30g/day in hypertensive patients. Whey also improves lipid profiles and supports lean body composition.

Best For: Muscle preservation, satiety, and modest BP reduction.

Dosing: 20-40g once or twice daily (often as a post-workout shake).

Cost: $30-$90/month.


Advanced Stack: Peptide Therapies

For patients with significant cardiovascular risk, metabolic dysfunction, or those seeking to optimize beyond the foundation stack, peptides offer powerful, targeted interventions. These are injectable compounds with strong RCT evidence.

GLP-1 Receptor Agonists (100-300mcg once or twice daily)

The Evidence: Semaglutide, a GLP-1 agonist, reduced systolic BP by 4.95 mmHg in a 3,136-patient meta-analysis over 68 weeks. Beyond BP reduction, GLP-1 agonists significantly improve lipid profiles, reduce body weight (mediated largely through appetite suppression), and reduce major adverse cardiovascular events.

Mechanism: GLP-1 agonists stimulate insulin secretion in response to glucose, slow gastric emptying, improve satiety signaling, and directly improve endothelial function.

Dosing: 100-300mcg injected once or twice daily (or weekly depending on formulation).

Best For: Type 2 Diabetes, obesity, or metabolic syndrome.

Cost: $40-$120/month.

Note: Gradual dose escalation is recommended to minimize nausea.


Retatrutide (2-12mg once weekly)

The Evidence: Retatrutide is a triple agonist of GLP-1, GIP, and glucagon receptors, offering more potent cardiovascular benefits than GLP-1 alone. A meta-analysis of RCTs found that retatrutide reduced systolic/diastolic BP by 9.88/3.88 mmHg in obese patients (n=878), significantly exceeding monotherapy benefits.

Mechanism: Triple receptor activation creates synergistic weight loss, improved insulin sensitivity, increased energy expenditure, and enhanced lipid metabolism.

Dosing: 2-12mg injected once weekly, with dose escalation based on tolerance and effect.

Best For: Obesity with cardiovascular disease, metabolic syndrome, Type 2 Diabetes.

Cost: $180-$520/month.

Note: This is among the most potent options for weight loss and cardiovascular risk reduction, but cost and accessibility remain limiting factors.


Gonadorelin (100-250mcg twice weekly)

The Evidence: GnRH antagonists (of which gonadorelin is a class member) are associated with 41% lower major adverse cardiovascular events compared to GnRH agonists in a meta-analysis of 123,969 prostate cancer patients (RR 0.59, 95% CI 0.41-0.84).

Best For: Prostate cancer patients or those seeking hormone optimization with reduced cardiovascular risk.

Dosing: 100-250mcg injected twice weekly (e.g., Monday and Thursday).

Cost: $40-$120/month.

Note: Evidence is strongest in specific populations; general cardiovascular benefits are modest compared to other peptides listed.


Tesamorelin (2mg once daily)

The Evidence: Tesamorelin demonstrates strong efficacy for reducing visceral adipose tissue by 15.2-24% over 26 weeks compared to 5% increase in placebo (double-blind RCTs, n=412-543). Visceral fat reduction directly improves cardiovascular risk markers: triglycerides, C-reactive protein, and carotid intima-media thickness.

Mechanism: Tesamorelin is a growth hormone-releasing hormone (GHRH) agonist that increases endogenous GH secretion, promoting visceral fat loss while sparing lean tissue.

Dosing: 2mg injected once daily.

Best For: Visceral obesity, metabolic syndrome, HIV lipodystrophy.

Cost: $80-$400/month (highly variable depending on source and dosing protocol).

Note: Evidence